View in EDS HTML Full Text PDF Full Text

Matrix metalloproteinase-3 serum levels in schizophrenic patients.

Saved in:
Bibliographic Details
Title: Matrix metalloproteinase-3 serum levels in schizophrenic patients.
Authors: Ordak, Michal, Libman-Sokolowska, Malgorzata, Nasierowski, Tadeusz, Badyra, Bogna, Kaczmarek, Leszek, Muszynska, Elzbieta, Bujalska-Zadrozny, Magdalena
Source: International Journal of Psychiatry in Clinical Practice. Mar2023, Vol. 27 Issue 1, p1-7. 7p.
Subjects: Drug therapy for schizophrenia, Matrix metalloproteinases, Sex distribution, Enzyme-linked immunosorbent assay, Questionnaires, Descriptive statistics, Antipsychotic agents
Abstract: It has been reported that matrix metalloproteinase, MMP-3 may play a significant role in the pathophysiology of mental disorders. However, there are no data on the level of MMP-3 in people suffering from schizophrenia, or its influence on the mental state of these people. The aim of this study was to investigate the effect of an antipsychotic treatment on the blood levels of MMP-3, as well as investigating its relationship with insight into schizophrenia. Thirty people with schizophrenia were included in the study. The concentration of MMP-3 in the blood serum was assessed using enzyme-linked immunosorbent assay. Insight into the disease was assessed using the Beck Cognitive Insight Scale. The antipsychotic treatment applied decreased the levels of MMP-3 in patients with schizophrenia (p = 0.005), however, the statistically significant interaction (p = 0.02) indicates that the decrease only concerned men. There was also a statistically significant correlation between the level of MMP-3 and insight into the disease (p = 0.02). MMP-3 may be associated with gender, treatment and symptoms in schizophrenic patients. MMP3 could be used as a potential biomarker for schizophrenia. The level of MMP-3 decreased due to the applied antipsychotic treatment. The higher the level of MMP-3 in a group of people with schizophrenia, the better insight into their disease. [ABSTRACT FROM AUTHOR]
Copyright of International Journal of Psychiatry in Clinical Practice is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 163696660
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Matrix metalloproteinase-3 serum levels in schizophrenic patients.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Ordak%2C+Michal%22">Ordak, Michal</searchLink><br /><searchLink fieldCode="AR" term="%22Libman-Sokolowska%2C+Malgorzata%22">Libman-Sokolowska, Malgorzata</searchLink><br /><searchLink fieldCode="AR" term="%22Nasierowski%2C+Tadeusz%22">Nasierowski, Tadeusz</searchLink><br /><searchLink fieldCode="AR" term="%22Badyra%2C+Bogna%22">Badyra, Bogna</searchLink><br /><searchLink fieldCode="AR" term="%22Kaczmarek%2C+Leszek%22">Kaczmarek, Leszek</searchLink><br /><searchLink fieldCode="AR" term="%22Muszynska%2C+Elzbieta%22">Muszynska, Elzbieta</searchLink><br /><searchLink fieldCode="AR" term="%22Bujalska-Zadrozny%2C+Magdalena%22">Bujalska-Zadrozny, Magdalena</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22International+Journal+of+Psychiatry+in+Clinical+Practice%22">International Journal of Psychiatry in Clinical Practice</searchLink>. Mar2023, Vol. 27 Issue 1, p1-7. 7p.
– Name: Subject
  Label: Subjects
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Drug+therapy+for+schizophrenia%22">Drug therapy for schizophrenia</searchLink><br /><searchLink fieldCode="DE" term="%22Matrix+metalloproteinases%22">Matrix metalloproteinases</searchLink><br /><searchLink fieldCode="DE" term="%22Sex+distribution%22">Sex distribution</searchLink><br /><searchLink fieldCode="DE" term="%22Enzyme-linked+immunosorbent+assay%22">Enzyme-linked immunosorbent assay</searchLink><br /><searchLink fieldCode="DE" term="%22Questionnaires%22">Questionnaires</searchLink><br /><searchLink fieldCode="DE" term="%22Descriptive+statistics%22">Descriptive statistics</searchLink><br /><searchLink fieldCode="DE" term="%22Antipsychotic+agents%22">Antipsychotic agents</searchLink>
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: It has been reported that matrix metalloproteinase, MMP-3 may play a significant role in the pathophysiology of mental disorders. However, there are no data on the level of MMP-3 in people suffering from schizophrenia, or its influence on the mental state of these people. The aim of this study was to investigate the effect of an antipsychotic treatment on the blood levels of MMP-3, as well as investigating its relationship with insight into schizophrenia. Thirty people with schizophrenia were included in the study. The concentration of MMP-3 in the blood serum was assessed using enzyme-linked immunosorbent assay. Insight into the disease was assessed using the Beck Cognitive Insight Scale. The antipsychotic treatment applied decreased the levels of MMP-3 in patients with schizophrenia (p = 0.005), however, the statistically significant interaction (p = 0.02) indicates that the decrease only concerned men. There was also a statistically significant correlation between the level of MMP-3 and insight into the disease (p = 0.02). MMP-3 may be associated with gender, treatment and symptoms in schizophrenic patients. MMP3 could be used as a potential biomarker for schizophrenia. The level of MMP-3 decreased due to the applied antipsychotic treatment. The higher the level of MMP-3 in a group of people with schizophrenia, the better insight into their disease. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of International Journal of Psychiatry in Clinical Practice is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=163696660
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/13651501.2022.2057332
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 1
    Subjects:
      – SubjectFull: Drug therapy for schizophrenia
        Type: general
      – SubjectFull: Matrix metalloproteinases
        Type: general
      – SubjectFull: Sex distribution
        Type: general
      – SubjectFull: Enzyme-linked immunosorbent assay
        Type: general
      – SubjectFull: Questionnaires
        Type: general
      – SubjectFull: Descriptive statistics
        Type: general
      – SubjectFull: Antipsychotic agents
        Type: general
    Titles:
      – TitleFull: Matrix metalloproteinase-3 serum levels in schizophrenic patients.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ordak, Michal
      – PersonEntity:
          Name:
            NameFull: Libman-Sokolowska, Malgorzata
      – PersonEntity:
          Name:
            NameFull: Nasierowski, Tadeusz
      – PersonEntity:
          Name:
            NameFull: Badyra, Bogna
      – PersonEntity:
          Name:
            NameFull: Kaczmarek, Leszek
      – PersonEntity:
          Name:
            NameFull: Muszynska, Elzbieta
      – PersonEntity:
          Name:
            NameFull: Bujalska-Zadrozny, Magdalena
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: Mar2023
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-print
              Value: 13651501
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: International Journal of Psychiatry in Clinical Practice
              Type: main
ResultId 1